Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
World Journal of Urology
Erschienen in: World Journal of Urology 3/2005

01.07.2005 | Topic Paper

Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment?

verfasst von: Jan Roigas, Gero Massenkeil

Erschienen in: World Journal of Urology | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Nonmyeloablative stem cell transplantation (NST) and donor lymphocyte infusions (DLI) are currently under clinical investigation as an innovative therapeutic option for patients with metastatic renal cell carcinoma (RCC). The underlying concept, adopted from patients with hematologic malignancies, aims at a reduction of conditioning toxicity and exploits the graft versus malignancy effect of donor T-lymphocytes after transplantation. Clinical data from more than 100 patients treated worldwide have been published so far. The data provide evidence that NST is feasible with a very low rate of engraftment failure. Objective remissions in these heterogenous studies were observed in 23% of the patients overall. Remissions after NST developed only after complete engraftment of donor lymphoid cells had occurred. Objective responses were almost always accompanied by graft versus host disease (GvHD) after withdrawal of immunosuppression and/or DLI. GvHD and infections were the main contributors to a substantial transplant related morbidity and mortality, the major drawback of allogeneic stem cell transplantation. Therefore, clinical studies are necessary to further investigate and improve the selection of patients with metastatic RCC or other solid tumors for NST and to reduce post-transplant complications. This article reviews the results, side effects and potential future developments of NST in the treatment of solid tumors.
Literatur
1.
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M (2003) Cancer Statistics, 2003. CA Cancer J Clin 53:5–26PubMed
2.
Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland (2004) Krebs in Deutschland. 4. Überarbeitete, aktualisierte Ausgabe. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland, Saarbrücken, (http://​www.​rki.​de/​KREBS)
3.
Mickisch GHJ, Garin A, Van Pappel H, De Prijck L, Sylvester R, and members of the European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group (2001) Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon-alpha alone in metastatic renal-cell-carcinoma: a randomised trial. Lancet 358:966–970CrossRefPubMed
4.
Levy DA, Slaton JW, Swanson DA, Dinney CP (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159:1163–1167CrossRef
5.
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492PubMed
6.
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JRJr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659CrossRefPubMed
7.
Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M (2004) Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–1194CrossRefPubMed
8.
Roigas J, Deger S, Taymoorian K, Wille AH, Johannsen M, Turk I, Schnorr D, Loening SA (2003) Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma--results of a retrospective analysis. Cancer Biother Radiopharm 18:157–163CrossRef
9.
Coppin C, Porzsolt F, Kumpf J, Coldmann A, Wilt T (2000) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 3:1–27 (CD001425)
10.
Negrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P, Gomez F (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18:4009–4015PubMed
11.
Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750–758CrossRefPubMed
12.
Jacobson LO, Simmons EL, Marks EK, Eldredge JH (1951) Recovery from radiation injury. Science 113:510–511
13.
Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068–1073PubMed
14.
Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y, Tsatalas C, Marcus RE, Goolden AW, Gordon-Smith EC (1986) Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1:53–66
15.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555–562PubMed
16.
Ringden O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC (1996) Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 18:921–929
17.
Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, Van Rhee F, Mittermueller J, De Witte T, Holler E, Ansari H for the European Group for Blood and Marrow Transplantation Working Party Chronic Leucemia (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041–2050PubMed
18.
Goulmy E (2004) Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J 10:1–7
19.
Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90:3204–3213
20.
Beelen DW, Haralambie E, Brandt H, Linzenmeier G, Muller KD, Quabeck K, Sayer HG, Graeven U, Mahmoud HK, Schaefer UW (1992) Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 80:2668–2676
21.
Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS, Barrett AJ (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234–3241PubMed
22.
Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O’Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531–4536PubMed
23.
Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematological diseases. Blood 91:756–763PubMed
24.
McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400CrossRefPubMed
25.
Mapara MY, Kim Y-M, Wang SP, Bronson R, Sachs DH, Sykes M (2002) Donor lymphocyte infusions (DLI) mediate superior graft-versus-leukemia (GvL) effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100:1903–1909CrossRef
26.
Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M, Prentice G, Garg M, Yin JA, Byrne J, Russell NH, Mufti GJ (2002) Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119:144–154CrossRef
27.
Dreger P, Van Biezen A, Brand R, Esteve J, Martino R, Deliliers GL, Hansz J, Fine J, Kimby E, Milligan D, Michallet M, Niederwieser DW (2003) Reduced-intensity conditioning lowers treatment-related mortality (TRM) of allogeneic stem cell transplantation (SCT) for CLL: A retrospective study on 448 patients. Blood 102:197a
28.
Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, Sandmaier BM, Storb R (2004) Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104:1550–1558CrossRefPubMed
29.
Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S (2001) Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. J Immunother 24:114–121CrossRef
30.
Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gassner C, Schiller L, Petersen F, Niederwieser D (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501–1508PubMed
31.
Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, Van Besien K, Hortobagyi GN, Champlin RE (1998) Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16:986–993PubMed
32.
Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, Dauplat J, Viens P, Faucher C, Blaise D (2002) Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 30:95–102CrossRef
33.
Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, DeKernion J, Belldegrun A (1997) Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 158:740–745CrossRef
34.
Fairlamb DJ (1981) Spontaneous regression of metastases of RCC: a report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 47:2102–2106
35.
Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS (1999) Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17:2521–2529
36.
Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG (2003) Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 21:884–890
37.
Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH (2003) Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 170:2727–2733
38.
Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20:2017–2024
39.
Blaise D, Bay JO, Faucher C et al. (2004) Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103:435–441CrossRefPubMed
40.
Massenkeil G, Roigas J, Nagy M, Wille A, Stroszczynski C, Mapara MY, Loening S, Dörken B, Arnold R (2004) Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 34:309–316CrossRef
41.
Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, Voena C, Zaniboni A, Bordignon C, Corradini P (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99:4234–4236CrossRef
42.
Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR (2002) Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94:2409–2415
43.
Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersall P, Pisa P, Martola J, Albiin N, Wernerson A, Soderberg M, Remberger M, Thorne A, Ringden O (2003) Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 31:253–261CrossRef
44.
Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE (2003) Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102:3829–3836CrossRef
45.
Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T, Kishi Y, Fujimoto H, Matsuoka N, Okajima E, Komiyama M, Tobisu K, Wakayama T, Uike N, Tajima K, Makimoto A, Mori S, Tanosaki R, Takaue Y, Kakizoe T (2004) Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Exp Hematol 32:599–606CrossRef
46.
Massenkeil G, Nagy M, Heine F, Le Coutre P, Neuburger S, Rosen O, Wernecke KD, Dörken B, Arnold R (2004) Survival after nonmyeloablative stem cell transplantation is comparable to conventional stem cell transplantation in acute leukemias. Onkologie 27 [Suppl 3]: abstract 290
47.
Mohty M, Faucher C, Vey N, Stoppa AM, Viret F, Chabbert I, Chabannon C, Bouabdallah R, Ladaique P, Collet L, Zandotti C, Maraninchi D, Blaise D (2000) High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 26:251–255CrossRef
48.
International Bone Marrow Transplant Registry (IBMTR) Database (2003) Current use and outcome of blood and marrow transplantation 2003. www.ibmtr.org
49.
Kernan NA (1999) T-cell depletion for the prevention of graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ (eds), Hematopoietic cell transplantation, 2nd edn. Blackwell Science, Malden, pp 186–196
50.
Baron F, Frere P, Baudoux E, Schaaf-Lafontaine N, Fillet G, Beguin Y (2003) Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update. Haematologica 88:835–837
51.
Sauer MG, Ericson ME, Weigel BJ, Herron MJ, Panoskaltsis-Mortari A, Kren BT, Levine BL, Serody JS, June CH, Taylor PA, Blazar BR (2004) A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Res 64:3914–3921
Metadaten
Titel
Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment?
verfasst von
Jan Roigas
Gero Massenkeil
Publikationsdatum
01.07.2005
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 3/2005
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-004-0480-2

Weitere Artikel der Ausgabe 3/2005

World Journal of Urology 3/2005 Zur Ausgabe

Topic Paper

Surgery for metastatic renal cell cancer

Topic Paper

Combination of surgery and immunotherapy in metastatic renal cell carcinoma

Topic Paper

Novel approaches in the therapy of metastatic renal cell carcinoma

Topic Paper

Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation

Topic Paper

Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells

Topic Paper

Immunotherapy in metastatic renal cell carcinoma

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise